Skip to main content
. Author manuscript; available in PMC: 2018 Apr 12.
Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2017 Nov 4;18(1):e61–e67. doi: 10.1016/j.clml.2017.10.006

Table 2. Comparison of VcR-CVAD with other intensive induction and consolidation regimens.

PFS OS
Intensive induction/consolidation
regimens
Nordic MCL2 (n=160)
R-maxi-CHOP/cytarabine		 6-year 66% 6-year 70%
GELA (n=60)
R-CHOP/R-DHAP		 Median 7 years 5-year 75%
CALGB 59909 (n=78) 5-year 56% 5-year 64%
R-hyper-CVAD (n=97)
Single-center		 3-year FFS 64% 3-year 82%
R-hyper-CVAD (n=60)
GISL		 5-year PFS 61% 5-year 73%
R-hyper-CVAD (n=49)
SWOG 0213		 Median 4.8 years Median 6.8 years
VcR-CVAD induction
maintenance rituximab
WON (n=30)
5 years MR		 6-year PFS 53%
6-year PFS 60% for age <60		 6-year 70%
E1405 (n=75)
2 years MR
22 received received ASCT		 3-year PFS 72%
3-year PFS 67% for MR-treated patients		 3-year 88%